Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9.

× No keyword cloud information.

18 in total

1. A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients.

Authors: Su-Jun Lee; Yin Jin Jang; Eun-Young Cha; Ho-Sook Kim; Sang Seop Lee; Jae-Gook Shin
Journal: Br J Clin Pharmacol Date: 2010-08 Impact factor: 4.335

Review 2. Pharmacogenetics of target genes across the warfarin pharmacological pathway.

Authors: Suman Lal; Srinivasa Rao Jada; Xiaoqiang Xiang; Wan-Teck Lim; Edmund J D Lee; Balram Chowbay
Journal: Clin Pharmacokinet Date: 2006 Impact factor: 6.447

Review 3. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors: K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal: Clin Pharmacokinet Date: 2000-02 Impact factor: 6.447

Review 4. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.

Authors: Julia Kirchheiner; Ivar Roots; Mark Goldammer; Bernd Rosenkranz; Jürgen Brockmöller
Journal: Clin Pharmacokinet Date: 2005 Impact factor: 6.447

5. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI).

Authors: K Pachkoria; M I Lucena; F Ruiz-Cabello; E Crespo; M R Cabello; R J Andrade
Journal: Br J Pharmacol Date: 2007-02-05 Impact factor: 8.739

6. Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.

Authors: Ji-Hong Shon; Young-Ran Yoon; Min-Jung Kim; Kyoung-Ah Kim; Young-Chae Lim; Kwang-Hyeon Liu; Dong-Hoon Shin; Chung Han Lee; In-June Cha; Jae-Gook Shin
Journal: Br J Clin Pharmacol Date: 2005-05 Impact factor: 4.335

Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9.

1. A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients.

Review 2. Pharmacogenetics of target genes across the warfarin pharmacological pathway.

Review 3. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Review 4. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.

5. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI).

6. Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.

7. A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: a pilot study.

8. Drug-induced liver graft toxicity caused by cytochrome P450 poor metabolism.

9. Dehydroepiandrosterone induces human CYP2B6 through the constitutive androstane receptor.

10. Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination.